Ikaria, Inc.

A randomized, double-blind, placebo-controlled, multi-center study of IK-1001 to evaluate safety, population pharmacokinetics and proof-of-concept efficacy for reduction of ischemia-reperfusion mediated cardiac injury in subjects undergoing coronary artery bypass graft (CABG) surgery.